Current status of treatment of type 2 diabetes mellitus in Ningbo, China

Abstract

The treatment status of type 2 diabetes mellitus (T2DM) in Ningbo has not been reported in the past. To evaluate the current status of T2DM in Ningbo and provide evidence to formulate more policies, a multicenter investigation was needed. The Ningbo Clinical Research Group of Diabetes constituted nine hospitals. Participants included 3015 patients who visited the nine hospitals from June to December 2016. General characteristics, the medication situation, the laboratory indexes in nearly 3months consisting of glycosylated hemoglobin level (HbA1c), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (FBG), and the results of ophthalmologic examination were investigated. The evaluation criteria were defined based on 2013 China guideline for T2DM. The 3015 subjects included 1685 men and 1330 women. The average age was 63.3±13.0years. The prevalence of hypertension and dyslipidemia was 58.7% and 56.7%, respectively. In the examinees, nephropathy appeared in 11.6% and retinopathy in 14.5%. More than half (50.9%) of the subjects were overweight. The achievement rate of blood pressure (BP) was 39.6% (<140/80mmHg), FBG was 46.0% (4.4-7.0mmol/L), HbA1c was 41.7% (<7.0%), and LDL-C was 51.7% (<1.8mmol/L; and if accompanied by CHD, <2.6). Ningbo City T2DM status is not optimistic, and there is a big gap with the indicators.